Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:37:23.315Z.
Calculation as of: 2026-10-06T21:37:23.315Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.40B
EV/Sales Ratio
183.11x
TTM Avg
230.35x
3Y Avg
103.32x
5Y Avg
91.50x
Market Cap
$1.39B
EV/Sales Ratio
1.70x
TTM Avg
1.63x
3Y Avg
1.71x
5Y Avg
1.70x
Market Cap
$1.42B
EV/Sales Ratio
3.49x
TTM Avg
5.14x
3Y Avg
6.51x
5Y Avg
7.91x
Market Cap
$1.37B
EV/Sales Ratio
N/A
TTM Avg
781.47x
3Y Avg
902.36x
5Y Avg
638.00x
Market Cap
$1.45B
EV/Sales Ratio
0.70x
TTM Avg
0.73x
3Y Avg
0.58x
5Y Avg
0.61x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 183.11x | 230.35x | 103.32x | 91.50x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 1.70x | 1.63x | 1.71x | 1.70x |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 6.54x | 6.81x | 12.09x | 18.83x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 3.49x | 5.14x | 6.51x | 7.91x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | 781.47x | 902.36x | 638.00x |
| Certara, Inc. (CERT)vs › | $1.44B | 3.79x | 3.18x | 5.10x | 7.42x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.70x | 0.73x | 0.58x | 0.61x |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 66.03x | 138.10x | 89.44x | 89.44x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
